D. Western Therapeutics Institute (FRA:6DW) Other Current Receivables: €0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:6DW D. Western Therapeutics Institute Inc FRA:6DW
29 GF Score
Price €0.37
GF Value €0.34
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is D. Western Therapeutics Institute Other Current Receivables?

D. Western Therapeutics Institute FRA:6DW +1.63% 29 Other Current Receivables is €0.00 Mil as of Dec. 2025. GuruFocus rates FRA:6DW with a GF Score™ of 29/100 and a GF Value™ of €0.34 (Fairly Valued). The stock has 3 warning signs investors should review.

D. Western Therapeutics Institute's Other Current Receivables for the quarter that ended in Dec. 2025 was €0.00 Mil.

D. Western Therapeutics Institute Other Current Receivables Related Terms

D. Western Therapeutics Institute Other Current Receivables Historical Data

* Premium members only.

The historical data trend for D. Western Therapeutics Institute's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

D. Western Therapeutics Institute Other Current Receivables Chart

D. Western Therapeutics Institute Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

D. Western Therapeutics Institute Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:6DW
29GF Score
D. Western Therapeutics Institute Inc FRA:6DW
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

D. Western Therapeutics Institute Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of €0.00 Mil mean?
D. Western Therapeutics Institute (FRA:6DW) has a Other Current Receivables of €0.00 Mil as of Dec. 2025. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on D. Western Therapeutics Institute and its competitors.
Is D. Western Therapeutics Institute's Other Current Receivables too high?
D. Western Therapeutics Institute's current Other Current Receivables is €0.00 Mil. Overall, D. Western Therapeutics Institute has a GF Score™ of 29/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does D. Western Therapeutics Institute's Other Current Receivables compare to VRTX and REGN?
D. Western Therapeutics Institute's Other Current Receivables of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Biotechnology company?
A good Other Current Receivables depends on the Biotechnology industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on D. Western Therapeutics Institute and its competitors. D. Western Therapeutics Institute's current Other Current Receivables is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is D. Western Therapeutics Institute stock overvalued right now?
Based on GuruFocus' analysis, D. Western Therapeutics Institute (FRA:6DW) is currently considered Fairly Valued. The stock's GF Value™ is €0.34, compared to a current price of €0.37 — trading 10% above its estimated fair value. The current Other Current Receivables is €0.00 Mil. D. Western Therapeutics Institute's overall GF Score™ is 29/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For D. Western Therapeutics Institute (FRA:6DW), the current Other Current Receivables is €0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is D. Western Therapeutics Institute (FRA:6DW) Overvalued in 2026?

Based on GuruFocus' analysis, D. Western Therapeutics Institute stock appears to be overvalued. The current stock price of €0.37 is trading 10% above its estimated GF Value™ of €0.34. GuruFocus considers D. Western Therapeutics Institute to be Fairly Valued.

Key valuation signals for FRA:6DW:

  • Other Current Receivables: €0.00 Mil
  • GF Value™: €0.34 vs. price of €0.37 (10% above fair value)
  • GF Score™: 29/100 with 3 warning signs

No single metric tells the full story. See the FRA:6DW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

D. Western Therapeutics Institute Business Description

Other Exchanges 4576:Japan
Address 7th Floor, 18 KT Bulding, 1-18-11, Nishiki, Naka-ku, Aichi, Nagoyashi, JPN, 460-0003
D. Western Therapeutics Institute Inc is engaged in the research and development of pharmaceutical drugs in Japan. Its products include ophthalmic solution and agents for antiplatelet and anti-glaucoma.
29GF Score

Get the complete analysis for FRA:6DW

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.37
Price
€0.34
GF Value